Efficacy of pamidronate in pediatric osteosarcoma patients with low bone mineral density
Annals of Pediatric Endocrinology & Metabolism
; : 21-25, 2016.
Article
en En
| WPRIM
| ID: wpr-34970
Biblioteca responsable:
WPRO
ABSTRACT
PURPOSE: Most surviving pediatric osteosarcoma patients experience osteoporosis, bone pain, and pathologic fracture during and after therapy. The aim of this study was to evaluate the efficacy and side effects of pamidronate therapy in these patients. METHODS: Nine osteosarcoma patients (12.8±1.6 years of age; 5 boys and 4 girls) who had a history of nontraumatic fracture or severe pain after completing chemotherapy were included. Intravenous pamidronate (1.5 mg/kg) was given every 6 weeks for 4 to 6 cycles. Bone mineral density (BMD) of the lumbar spine was measured by dual-energy x-ray absorptiometry. Clinical outcomes including acute side effects were also evaluated. RESULTS: After pamidronate treatments, all patients experienced decreased pain. Seven of 9 patients could walk without a crutch. The BMD of lumbar spine was increased by 0.108±0.062 mg/cm2 after 8.4±1.0 months (n=8, P=0.017) and the mean z-score improved from -2.14±0.94 to -1.76±0.95 (P=0.161). Six patients (67%) had an acute-phase reaction, and 2 patients had symptomatic hypocalcemia. CONCLUSION: Pamidronate appears to be safe and effective for the treatment of osteosarcoma in children with low BMD and bone pain.
Palabras clave
Texto completo:
1
Base de datos:
WPRIM
Asunto principal:
Osteoporosis
/
Columna Vertebral
/
Osteosarcoma
/
Absorciometría de Fotón
/
Densidad Ósea
/
Reacción de Fase Aguda
/
Quimioterapia
/
Fracturas Espontáneas
/
Hipocalcemia
Límite:
Child
/
Humans
Idioma:
En
Revista:
Annals of Pediatric Endocrinology & Metabolism
Año:
2016
Tipo del documento:
Article